Advertisement

Basic Principles of Radiobiology

  • Kathleen C. Horst
  • Amato J. Giaccia
Chapter

Abstract

The therapeutic benefit of radiation in the treatment of breast cancer was first noted by Emil Grubbé in January 1896 in Chicago. Less than 60 days after the discovery of X-rays by Wilhelm Conrad Röntgen in Germany in 1895, Grubbé successfully treated an advanced ulcerated breast cancer. The first treatment complications were also noted during these early years of radiotherapy. In 1922, the first case of lung fibrosis after the treatment of breast cancer was described, leading to changes in the radiation techniques used to treat the breast and chest wall. Advances in radiation physics and biology over the past several decades have built upon these early observations to develop more effective and less harmful treatments. This chapter reviews general principles of radiobiology as they apply to breast cancer.

Keywords

Breast Cancer Homologous Recombination Hypoxic Cell Ataxia Telangiectasia Ataxia Telangiectasia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Suggested Reading

  1. •Berenier J, Hall EJ, Giaccia A. Radiation oncology: a century of achievements. Nat Rev. 2004;4:737–47.Google Scholar
  2. •Grubbé EH. Priority in the therapeutic use of X-rays. Radiology. 1933;21:156–62.Google Scholar
  3. •Glasser O. Wilhelm Conrad Röntgen and the early history of Rontgen rays. Berlin: Julius Springer; 1931.Google Scholar
  4. •Regaud C, Ferroux R. Discordance des effects de rayons X, d’une part dans le testicile, par le peau, d’autre parts dans le fractionment de la dose. Compt Rend Soc Biol. 1927;97:431–4.Google Scholar
  5. •Coutard H. Principles of X-ray therapy of malignant disease. Lancet. 1934;2:1–12.CrossRefGoogle Scholar
  6. •Baclesse F. Comparative study of results obtained with conventional radiotherapy (200kV) and coalt therapy in the treatment of cancer of the larynx. Clin Radiol. 1967;18:292–300.PubMedCrossRefGoogle Scholar
  7. •Thomlinson RH, Gray LH. The histologic structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955;9:539–49.PubMedCrossRefGoogle Scholar
  8. •Puck TT, Marcus PI. Action of X-rays on mammalian cells. J Exp Med. 1956;103:653–66.PubMedCrossRefGoogle Scholar
  9. •Hewitt HB, Wilson CW. A survival curve for mammalian leukaemia cells irradiated in vivo (implications for the treatment of mouse leukaemia by whole-body irradiation). Br J Cancer. 1959;13:69–75.PubMedCrossRefGoogle Scholar
  10. •Withers HR. Regeneration of intestinal mucosa after irradiation. Cancer. 1971;28:75–81.PubMedCrossRefGoogle Scholar
  11. •Withers HR. In: Lett J, Adler H, editors. Advances in radiation biology, vol 5. Academic Press: New York; 1975. p. 241–71.Google Scholar
  12. •Elkind MM, Sutton-Gilbert H, Moses WB, et al. Radiation response of mammalian cells in culture: V. Temperature dependence of the repair of X-ray damage in surviving cells (aerobic and hypoxic). Radiat Res. 1965;25:359–76.PubMedCrossRefGoogle Scholar
  13. •Hall EJ, Giaccia AJ. Radiobiology for the radiologist, 6th ed. Lippincott Williams & Wilkins; Philadelphia, PA. 2006.Google Scholar
  14. •van Putten LM, Kallman RF. Oxygenation status of a transplantable tumor during fractionated radiotherapy. J Natl Cancer Inst. 1968;40:441–51.PubMedGoogle Scholar
  15. •Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239–57.PubMedCrossRefGoogle Scholar
  16. •Lowe SW, Ruley HE, Jackes T, Housman DE. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957–67.PubMedCrossRefGoogle Scholar
  17. •Tutt A, Yarnold J. Radiobiology of Breast Cancer. Clin Oncol. 2006;18:166–78.CrossRefGoogle Scholar
  18. •EBCTCG. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists Collaborative Group. Lancet. 2000;355:1757–70.Google Scholar
  19. •Owen JR, Ashton A, Bliss J, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomized trial. Lancet Oncol. 2006;7:467–71.PubMedCrossRefGoogle Scholar
  20. •Yarnold J, Ashton A, Bliss J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomized trial. Radiother Oncol. 2005;75:9–17.PubMedCrossRefGoogle Scholar
  21. •The START Trialists’ Group. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet Oncol. 2008;9:331–41.Google Scholar
  22. •The START Trialists’ Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet. 2008;371:1098–107.Google Scholar
  23. •Whelan T, MacKenzie R, Julian J, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst. 2002;94:201043–50.CrossRefGoogle Scholar
  24. •Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007;25(22):3259–65.PubMedCrossRefGoogle Scholar
  25. •Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in-situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001;28:400–18.PubMedCrossRefGoogle Scholar
  26. •Bijker N, Peterse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast conserving therapy for ductal carcinoma in-situ: analysis of European Organisation for Research and Treatment of Cancer trial 10853. J Clin Oncol. 2001;19(8):2263–71.PubMedGoogle Scholar
  27. •van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcionam in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988;319:1239–45.PubMedCrossRefGoogle Scholar
  28. •Syllaba K, Henner K. Contribution a l’independence de l’athetose double idiopathique et congenitale. Atteinte familiale, syndrome dystrophique, signe de reseau vasculaire conjonctival, integrite psychique. Rev Neurol. 1926;1:541–62.Google Scholar
  29. •Gotoff SP, Amirmokri E, Liebner EJ. Ataxia telangiectasia, Neoplasia, untoward response to X-irradiation, and tuberous sclerosis. Am J Dis Child. 1967;20104:617–25.Google Scholar
  30. •Taylor AMR et al. Ataxia-telangiectasia: a human mutation with abnormal radiation sensitivity. Nature. 1975;4:427–9.CrossRefGoogle Scholar
  31. •Folkman J. In: Braunwald E, et al., editors. Harrison’s textbook of internal medicine, 15th ed. McGraw-Hill: New York; 2001. p. 517–30.Google Scholar
  32. •Garcia-Barros M et al. Tumour response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300:201055–9.CrossRefGoogle Scholar

Copyright information

© Springer New York 2010

Authors and Affiliations

  1. 1.Department of Radiation OncologyStanford University School of MedicineStanfordUSA

Personalised recommendations